Preclinical evaluation of Amblyomin-X, a Kunitz-type protease inhibitor with antitumor activity
Amblyomin-X, a Kunitz-type protease inhibitor, is a recombinant protein that selectively induces apoptosis in tumor cells and promotes tumor reduction in vivo in melanoma animal models. Furthermore, Amblyomin-X was able to drastically reduce lung metastasis in a mice orthotopic kidney tumor model. D...
Main Authors: | Durvanei A. Maria, Sonia Elisabete A.L. Will, Rosemary V. Bosch, Jean G. Souza, Juliana M. Sciani, Mauricio B. Goldfeder, Giuliana G. Rondon, Ana M. Chudzinski-Tavassi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-01-01
|
Series: | Toxicology Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214750018305468 |
Similar Items
-
Dynein function and protein clearance changes in tumor cells induced by a Kunitz-type molecule, Amblyomin-X.
by: Mario T F Pacheco, et al.
Published: (2014-01-01) -
Amblyomin-X, a recombinant Kunitz-type inhibitor, regulates cell adhesion and migration of human tumor cells
by: Mariana Costa Braga Schmidt, et al.
Published: (2020-01-01) -
New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X
by: Lorena Favaro Pavon, et al.
Published: (2019-07-01) -
Avaliação dos efeitos de um inibidor do tipo Kunitz (Amblyomin-X) em culturas celulares de carcinoma renal
by: Akagi, Erica Mie [UNIFESP]
Published: (2015) -
Corrigendum to “Pro-apoptotic effects of Amblyomin-X in murine renal cell carcinoma “in vitro” [Biomed. Pharmacother. 66 (2012) 64–69]
by: Erica Mie Akagi, et al.
Published: (2019-10-01)